Compugen (CGEN) to Release Earnings on Tuesday

Compugen (NASDAQ:CGEN) is set to announce its earnings results before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of $0.21 per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.06. The business had revenue of $6.70 million for the quarter, compared to analyst estimates of $2.68 million. During the same period in the prior year, the company earned ($0.11) EPS. On average, analysts expect Compugen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Compugen Stock Performance

Compugen stock traded up $0.01 during midday trading on Tuesday, reaching $1.65. The company’s stock had a trading volume of 43,411 shares, compared to its average volume of 405,304. Compugen has a fifty-two week low of $0.53 and a fifty-two week high of $3.03. The firm has a market capitalization of $147.25 million, a PE ratio of -16.40 and a beta of 2.64. The stock’s 50 day simple moving average is $1.81 and its 200 day simple moving average is $1.89.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of Compugen from a “hold” rating to a “buy” rating in a research report on Thursday, August 15th.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.